Size of risk groups and outcomes using a rank-based approach
| Rank-based approach . | ||||
|---|---|---|---|---|
| Model building . | Validation cohort . | |||
| High risk . | ||||
| A-HIPI Patient rank (percentile) . | A-HIPI cutoffs . | Observed PFS5 <cutoff . | % of pts <cutoff . | Observed PFS5 <cutoff . |
| 5% | <0.646 | 59.3 | 6% | 65.5 |
| 10% | <0.686 | 61.6 | 13% | 65.6 |
| 25% (quartile 1) | <0.737 | 66.1 | 27% | 71.4 |
| 33% (tertile) | <0.754 | 68.5 | 34% | 72.4 |
| 50% (median) | <0.781 | 71.5 | 49% | 74.6 |
| Low risk | ||||
| Patient rank (percentile) | A-HIPI cutoffs | Observed PFS5 >cutoff | % of pts >cutoff | Observed PFS5 >cutoff |
| 50% (median) | >0.781 | 82.3 | 51% | 81.7 |
| 67% (tertile) | >0.806 | 83.3 | 35% | 83.2 |
| 75% (quartile 3) | >0.818 | 83.8 | 27% | 85.8 |
| 90% | >0.844 | 86.0 | 13% | 86.9 |
| 95% | >0.857 | 85.6 | 7% | 88.2 |
| Rank-based approach . | ||||
|---|---|---|---|---|
| Model building . | Validation cohort . | |||
| High risk . | ||||
| A-HIPI Patient rank (percentile) . | A-HIPI cutoffs . | Observed PFS5 <cutoff . | % of pts <cutoff . | Observed PFS5 <cutoff . |
| 5% | <0.646 | 59.3 | 6% | 65.5 |
| 10% | <0.686 | 61.6 | 13% | 65.6 |
| 25% (quartile 1) | <0.737 | 66.1 | 27% | 71.4 |
| 33% (tertile) | <0.754 | 68.5 | 34% | 72.4 |
| 50% (median) | <0.781 | 71.5 | 49% | 74.6 |
| Low risk | ||||
| Patient rank (percentile) | A-HIPI cutoffs | Observed PFS5 >cutoff | % of pts >cutoff | Observed PFS5 >cutoff |
| 50% (median) | >0.781 | 82.3 | 51% | 81.7 |
| 67% (tertile) | >0.806 | 83.3 | 35% | 83.2 |
| 75% (quartile 3) | >0.818 | 83.8 | 27% | 85.8 |
| 90% | >0.844 | 86.0 | 13% | 86.9 |
| 95% | >0.857 | 85.6 | 7% | 88.2 |
A-HIPI, advanced-stage Hodgkin lymphoma international prognostic index; PFS5, 5-year progression-free survival; pts, patients.